291 related articles for article (PubMed ID: 24127063)
21. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.
Wu SJ; Kuo YY; Hou HA; Li LY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Lin CT; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tang JL; Tsay W; Tien HF
Blood; 2012 Oct; 120(15):3106-11. PubMed ID: 22932795
[TBL] [Abstract][Full Text] [Related]
22. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
23. Monosomal karyotype in MDS: explaining the poor prognosis?
Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Grau J; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
Leukemia; 2013 Oct; 27(10):1988-95. PubMed ID: 23787396
[TBL] [Abstract][Full Text] [Related]
24. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
[TBL] [Abstract][Full Text] [Related]
25. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract][Full Text] [Related]
26. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
27. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
29. Detection of SRSF2-P95 mutation by high-resolution melting curve analysis and its effect on prognosis in myelodysplastic syndrome.
Lin J; Yang J; Wen XM; Yang L; Deng ZQ; Qian Z; Ma JC; Guo H; Zhang YY; Qian W; Qian J
PLoS One; 2014; 9(12):e115693. PubMed ID: 25541999
[TBL] [Abstract][Full Text] [Related]
30. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
31. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
32. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
33. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
[TBL] [Abstract][Full Text] [Related]
34. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
35. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.
Adema V; Larráyoz MJ; Calasanz MJ; Palomo L; Patiño-García A; Agirre X; Hernández-Rivas JM; Lumbreras E; Buño I; Martinez-Laperche C; Mallo M; García O; Álvarez S; Blazquez B; Cervera J; Luño E; Valiente A; Vallespí MT; Arenillas L; Collado R; Pérez-Oteyza J; Solé F
Br J Haematol; 2015 Oct; 171(1):137-41. PubMed ID: 25716545
[No Abstract] [Full Text] [Related]
36. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract][Full Text] [Related]
37. [Investigation of FLT3-ITD and NPM1 mutations in patients with myelodysplastic syndrome and mixed myeloid diseases].
Gritsaev SV; Martynkevich IS; Ivanova MP; Moskalenko MV; Aksenova VIu; Tiranova SA; Abdulkadyrov KM
Vopr Onkol; 2010; 56(6):671-6. PubMed ID: 21395122
[TBL] [Abstract][Full Text] [Related]
38. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.
Sánchez-Castro J; Marco-Betés V; Gómez-Arbonés X; Arenillas L; Valcarcel D; Vallespí T; Costa D; Nomdedeu B; Jimenez MJ; Granada I; Grau J; Ardanaz MT; de la Serna J; Carbonell F; Cervera J; Sierra A; Luño E; Cervero CJ; Falantes J; Calasanz MJ; González-Porrás JR; Bailén A; Amigo ML; Sanz G; Solé F
Leuk Res; 2013 Jul; 37(7):769-76. PubMed ID: 23639672
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.
Chen TC; Hou HA; Chou WC; Tang JL; Kuo YY; Chen CY; Tseng MH; Huang CF; Lai YJ; Chiang YC; Lee FY; Liu MC; Liu CW; Liu CY; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2014 Jan; 4(1):e177. PubMed ID: 24442206
[TBL] [Abstract][Full Text] [Related]
40. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
